Weight loss drug alli could reduce dangerous diabetes fat

Fri, 29 Jan 2010
alli, an over-the-counter weight loss drug approved by the Food and Drug Administration in America has been clinically proven to reduce levels of visceral fat . This type of bodily fat, which typically collects around the abdomen, is widely associated with type 2 diabetes risk. Recent news reports highlighted that fat in the thighs and rear actually indicated a lower risk of diabetes .

alli, which is also called orlistat, has been shown to lower weight when combined with a reduced calorie, lower-fat diet . Clinical trials indicate a boost in weight loss by as much as 50 per cent. The drug works by stopping fat being absorbed in the digestive tract.

Whether or not alli has a role in diabetes care, it is strongly worth understanding the risks of visceral fat . This type of fat surrounds major organs in the abdomen and prevents their normal functioning. Even slight levels of weight loss can lower visceral fat and improve health considerably.

One American expert, Dr. Albu of the St. Luke's-Roosevelt Hospital Center in New York, confirmed the need to understand this type of fat: "Although most individuals try to lose weight to improve their appearance, it's important to help them understand that losing excess fat reduces their risks of life-threatening diseases. We need to raise awareness of the direct link between visceral fat on the inside and heart disease and diabetes. Through healthy eating, keeping active and treatments such as alli, people can lose 5 to 10 percent of total body weight - including visceral fat - and achieve and maintain their healthy weight ."
Leave a Comment
Login via Facebook, Yahoo! and Hotmail
or
Have your full say in the Diabetes Forum
Your comments may be moderated. Please report any spam, illegal, offensive or libellous posts.